• In February 2026, Science Applications International Corp. lowered its fiscal 2027 revenue guidance to US$7.0–US$7.2 billion amid unfavorable contract recompete outcomes and also named long-time government services executive Jim Reagan as permanent CEO, while launching the Alliance for Advancing Rural Healthcare to support a major federal rural health modernization program.
• Together, the weaker revenue outlook and expansion into rural healthcare solutions highlight a company balancing contract pressures with efforts to broaden its role in federally funded transformation initiatives.
• We’ll now examine how the lowered revenue guidance, alongside the rural healthcare alliance launch, reshapes Science Applications International’s investment narrative.

Uncover the next big thing with 32 elite penny stocks that balance risk and reward.

Science Applications International Investment Narrative Recap

To own Science Applications International today, you need to believe its government IT and mission services franchise can absorb contract setbacks while still converting its bid pipeline into sustainable revenue and cash flow. The lowered fiscal 2027 revenue guidance makes recompete risk the key near term swing factor, while the biggest risk remains ongoing funding pressure and competition in federal IT, which could keep growth subdued if contract losses like the recent ones continue.

Among the latest developments, the launch of the Alliance for Advancing Rural Healthcare stands out as most relevant. It ties SAIC’s core strengths in AI, data, and cybersecurity to one of the largest federal rural health programs, potentially reinforcing its role in complex, long duration government modernization efforts at a time when traditional recompetes have turned against it.

Yet while the rural healthcare initiative looks promising, investors should be aware that contract recompete risk and budget pressure could still...

Science Applications International's narrative projects $7.7 billion revenue and $344.8 million earnings by 2028.

Uncover how Science Applications International's forecasts yield a $113.38 fair value, a 26% upside to its current price.

Exploring Other Perspectives

Some analysts were far more optimistic, assuming revenue could reach about US$8.5 billion and earnings about US$438.7 million, yet today’s guidance cut and contract losses could cause both that upbeat backlog story and the risk of federal budget pressure to be reassessed.

Explore 4 other fair value estimates on Science Applications International - why the stock might be worth over 2x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Science Applications International research is our analysis highlighting 5 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Science Applications International research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Science Applications International's overall financial health at a glance.

Searching For A Fresh Perspective?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Outshine the giants: these 24 early-stage AI stocks could fund your retirement.
• Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.
• This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.